SequelSEC

PURE BIOSCIENCE, INC. PURE

Miscellaneous Chemical Products · CIK 0001006028 · Fiscal year ends 0731

Revenue
$2.32M
Fiscal year ended 2026-07-31
Operating income
-$2.08M
Fiscal year ended 2026-07-31
Free cash flow
Unavailable
Fiscal year ended 2026-07-31

Valuation, from the filing

Public float$4.67MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-01-31
Float per share$0.04Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-01-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-07-31 — the year that filing covered.

How this compares in its industry

Percentile among the Miscellaneous Chemical Products filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin57.3%100th
Net margin-107.3%12th
Operating margin-90.0%12th
R&D / revenue14.3%88th
SBC / revenue8.5%88th
Current ratio0.27x25th
Revenue YoY growth5.3%75th

PURE BIOSCIENCE, INC. (PURE) reported revenue of $2.32M and net income of -$2.48M for the fiscal year ended 2026-07-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PURE BIOSCIENCE, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Miscellaneous Chemical Products.

Income

PURE BIOSCIENCE, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312025-07-312024-07-312023-07-312022-07-312021-07-312020-07-312019-07-312018-07-312017-07-31
Revenue$2.32M$2.20M$1.96M$1.87M$1.81M$3.70M$6.92M$1.91M$1.77M$1.83M
Cost of revenue$992.00K$899.00K$811.00K$906.00KUnavailableUnavailable$2.90M$728.00K$763.00K$760.00K
Gross profit$1.33M$1.30M$1.15M$971.00KUnavailableUnavailable$4.02M$1.18M$1.01M$1.07M
Operating income-$2.08M-$2.27M-$3.19M-$3.94M-$3.72M-$2.31M$4.00K-$5.59M-$7.04M-$6.01M
Net income-$2.48M-$2.40M-$3.35M-$3.96M-$3.49M-$2.32M$4.00K-$6.55M-$7.44M-$6.26M
Research & development$332.00K$316.00K$302.00K$297.00K$319.00K$339.00K$322.00K$354.00K$459.00K$779.00K
Weighted-average diluted sharesshares 116.46Mshares 111.86Mshares 111.86Mshares 111.40Mshares 88.84Mshares 87.17Mshares 84.61Mshares 72.88MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$1.65K$1.65K$1.65K$1.65K$1.65K$1.65K
Diluted EPS$-0.02$-0.02$-0.03$-0.04$-0.04$-0.03$0.00$-0.09UnavailableUnavailable
Selling, general & administrative$3.08M$3.26M$3.98M$4.30M$4.05M$4.05M$3.70M$6.42M$5.24M$5.23M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PURE BIOSCIENCE, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312025-07-312024-07-312023-07-312022-07-312021-07-312020-07-312019-07-312018-07-312017-07-31
Cash & equivalents$569.00K$334.00K$349.00K$1.10M$3.39M$2.39M$3.84M$398.00K$851.00K$1.64M
Total assets$1.19M$1.06M$818.00K$1.82M$4.48M$4.30M$6.32M$1.93M$2.58M$3.83M
Current assets$1.18M$1.05M$805.00K$1.60M$3.86M$3.20M$5.57M$1.04M$1.46M$2.46M
Total liabilities$7.59M$6.17M$3.68M$1.55M$575.00K$970.00K$1.51M$742.00K$1.29M$2.54M
Current liabilities$4.37M$2.11M$733.00K$532.00K$575.00K$970.00K$1.51M$738.00K$1.28M$2.53M
Total equity incl. NCI-$6.40M-$5.12M-$2.86M$272.00K$3.91M$3.33M$4.81M$1.19M$1.28M$1.29M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$193.00K$141.00K$56.00K$88.00K$179.00K$332.00K$547.00K$177.00K$197.00K$273.00K
Accounts receivable$334.00K$474.00K$298.00K$285.00K$201.00K$368.00K$1.09M$373.00K$275.00K$297.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$6.60MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$820.00K$784.00K$601.00K$422.00K$488.00K$593.00K$1.34M$553.00K$608.00K$426.00K

Cash flow

PURE BIOSCIENCE, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312025-07-312024-07-312023-07-312022-07-312021-07-312020-07-312019-07-312018-07-312017-07-31
Operating cash flow-$1.74M-$2.02M-$2.53M-$3.28M-$2.42M-$1.17M$669.00K-$2.99M-$3.89M-$4.56M
Capital expendituresUnavailableUnavailableUnavailable$33.00K$81.00K$521.00K$58.00K$7.00K$19.00K$206.00K
Investing cash flowUnavailableUnavailableUnavailable-$33.00K-$81.00K-$521.00K-$58.00K-$13.00K-$34.00K-$226.00K
Financing cash flow$1.97M$2.00M$1.78M$1.02M$3.50M$239.00K$2.83M$2.55M$3.13M$1.23M
Net change in cash$235.00K-$15.00K-$746.00K-$2.30M$1.00M-$1.45M$3.44M-$453.00K-$789.00K-$3.55M
Stock-based compensation$197.00K$147.00K$214.00K$324.00K$567.00K$841.00K$787.00K$2.45M$2.36M$1.07M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.00K$2.00K$148.00K$117.00K$213.00K$172.00K$192.00K$241.00K$285.00K$276.00K

Derived

PURE BIOSCIENCE, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312025-07-312024-07-312023-07-312022-07-312021-07-312020-07-312019-07-312018-07-312017-07-31
Free cash flowUnavailableUnavailableUnavailable-$3.31M-$2.50M-$1.69M$611.00K-$3.00M-$3.91M-$4.77M
Gross margin57.3%59.3%58.9%51.9%55.2%56.1%58.1%61.9%57.0%58.5%
Operating margin-90.0%-103.4%-163.2%-210.7%-205.4%-62.5%0.1%-292.8%-397.0%-328.1%
FCF marginUnavailableUnavailableUnavailable-177.0%-137.8%-45.6%8.8%-157.0%-220.2%-260.4%
SBC / revenue8.5%6.7%10.9%17.3%31.3%22.7%11.4%128.3%133.0%58.4%
Current ratio0.27x0.50x1.10x3.02x6.72x3.30x3.68x1.41x1.14x0.97x
Revenue YoY growth5.3%12.4%4.5%3.2%-51.0%-46.5%262.3%7.6%-3.1%Unavailable
Net margin-107.3%-109.1%-171.4%-211.7%-192.6%-62.7%0.1%-343.3%-419.5%-342.1%
R&D / revenue14.3%14.4%15.4%15.9%17.6%9.2%4.7%18.5%25.9%42.5%
CapEx / revenueUnavailableUnavailableUnavailable1.8%4.5%14.1%0.8%0.4%1.1%11.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PURE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-12-15View SEC filing
10-K · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-06-16View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2022-07-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2021-07-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.